The phase 3 study is the first pivotal gene therapy trial to evaluate OCU410 in patients with GA secondary to dAMD. The FDA ...
The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug ...
Zacks Investment Research on MSN
OCGN advances gene therapy OCU410 in phase III for geographic atrophy
Ocugen OCGN announced that it has dosed the first patient in the global phase III ArMaDa3 study evaluating the modifier gene therapy candidate, OCU410, for treating geographic atrophy (“GA”) secondary ...
GlobalData on MSN
Ocugen begins Phase III trial of OCU410 gene therapy for GA
The Phase III study randomises GA patients in 2:1 ratio to receive either OCU410 or no treatment.
Ocugen OCGN is advancing a retinal pipeline built around durability and breadth. Its focus is a modifier gene therapy platform aimed at inherited retinal diseases and blindness conditions, using ...
Arshad Khanani, MD, explains why gene therapy for wet age-related macular degeneration (AMD) is close to becoming a real-world option for the masses. Khanani explains why long-term phase 1/2 data have ...
Missed injections for weeks or months can trigger vision damage that isn't always fully reversible in patients with neovascular age-related macular degeneration (wet AMD), according to Carl Regillo, ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results